Literature DB >> 28481454

Severe Acute Valproic Acid Intoxication Successfully Treated with Liver Support Therapy.

Yongchun Ge1, Bin Xu1, Shuhua Zhu1, Chuan Li1, Qunpeng He1, Tingting Zhu2, Rong Fan1, Dehua Gong1.   

Abstract

Valproic acid (VPA) is widely used for the treatment of epilepsy. However, its overdose can cause intoxication and could be life-threatening. Due to the lack of specific antidote and poorness of endogenous clearance, extracorporeal treatment for severe intoxication cases is indicated. Here, we report a case of severe intoxication of VPA which was successfully treated with liver support therapy. A previously healthy woman was admitted due to coma and hypotension after intentional ingestion of 20 g of sodium valproate. Her serum concentration of VPA measured on admission was 420.84 mg/L. In addition to standard therapy, she received two sessions of extracorporeal blood purification using a system based on fractionated plasma separation and adsorption mode integrated with continuous veno-venous haemofiltration (FPSA-CVVH), which is usually used for liver support therapy at our hospital. Her serum concentration of VPA decreased dramatically to 40.18 mg/L and her consciousness recovered completely within 24 hr after admission. Therefore, although haemodialysis has been reported to be effective in the treatment for VPA poisoning, FPSA-CVVH may provide an option for patients who require bedside therapy but have an unstable haemodynamic status or other conditions that result in inability to endure haemodialysis.
© 2017 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28481454     DOI: 10.1111/bcpt.12807

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  1 in total

1.  Hemodiafiltration Treatment for Severe Valproic Acid Intoxication: Case Report and Updated Systematic Literature Review.

Authors:  Tobias Tichelbäcker; Judith Herath; Björn Tampe; Peter Korsten
Journal:  Front Med (Lausanne)       Date:  2018-08-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.